Neuroprotective therapy in advanced primary open-angle glaucoma
Long-term neuroretinoprotective therapy with Retinalamin (Geropharm, Russia) in patients with advanced POAG is justified when administered regularly and the intraocular pressure is stable and well controlled.
Authors
- D.A. Dorofeev
- A. O. Vereshchagina (ORCID: https://orcid.org/0000-0001-5606-4335)
- I. A. Kozlova
Institutions
- Pirogov Russian National Research Medical University (RU)
- Federal State Scientific Institution Research Institute of Eye Diseases (RU)
- St. Petersburg State Medical Academy "City Polyclinic №44" (RU)
- Municipal Autonomous Healthcare Institution (RU)
Publication Details
- Journal
- Russian Annals of Ophthalmology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.17116/oftalma202514106175
- Primary Topic
- Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00